Is MiMedx Group, Inc. overvalued or undervalued?

As of 26 February 2025, the valuation grade for MiMedx Group, Inc. has moved from attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 24, an EV to EBITDA of 14.64, and a ROCE of 47.22%.
In comparison to peers, MiMedx's P/E ratio of 21.59 is significantly lower than that of LeMaitre Vascular, Inc., which stands at 43.25, indicating a relative undervaluation in the context of its industry. Additionally, while MiMedx shows a strong ROE of 19.84%, it is essential to note the recent stock performance, which has underperformed against the S&P 500, particularly over the past year with a decline of 13.54% compared to the index's gain of 10.26%.